Current and Future Perspectives of Cell-Free DNA in Liquid Biopsy.
Current and Future Perspectives of Cell-Free DNA in Liquid Biopsy.
复制标题
DOI：
10.3390/cimb44060184
复制
发表时间：
2022-06-10
影响因子：
3.1
通讯作者：
Wang, Jinke
中科院分区：
文献类型：
--
作者：
Liu, Shicai;Wang, Jinke
液体活检是一种微创或无创方法，用于分析血液或其他体液中的一系列肿瘤物质，包括循环肿瘤细胞（CTC）、游离DNA（cfDNA）、信使RNA（mRNA）、微小RNA（miRNA）和外泌体，是一项非常有前途的技术。在这些癌症生物标志物中，血浆cfDNA在临床实践中应用最广泛。与传统癌症诊断的组织活检相比，在评估肿瘤异质性时，液体活检更可靠，因为所有肿瘤部位都会将cfDNA释放到血液中。因此，cfDNA 液体活检侵入性较小且全面。而且，新一代测序技术的发展使得cfDNA测序比组织活检更加灵敏，临床适用性更高，应用范围更广。在本出版物中，我们旨在综述 cfDNA 液体活检的临床意义及其在癌症诊断、治疗和预后中的应用的最新观点。我们介绍了cfDNA检测、分析和临床应用的测序技术和挑战，并讨论了未来的研究方向。
A liquid biopsy is a minimally invasive or non-invasive method to analyze a range of tumor material in blood or other body fluids, including circulating tumor cells (CTCs), cell-free DNA (cfDNA), messenger RNA (mRNA), microRNA (miRNA), and exosomes, which is a very promising technology. Among these cancer biomarkers, plasma cfDNA is the most widely used in clinical practice. Compared with a tissue biopsy of traditional cancer diagnosis, in assessing tumor heterogeneity, a liquid biopsy is more reliable because all tumor sites release cfDNA into the blood. Therefore, a cfDNA liquid biopsy is less invasive and comprehensive. Moreover, the development of next-generation sequencing technology makes cfDNA sequencing more sensitive than a tissue biopsy, with higher clinical applicability and wider application. In this publication, we aim to review the latest perspectives of cfDNA liquid biopsy clinical significance and application in cancer diagnosis, treatment, and prognosis. We introduce the sequencing techniques and challenges of cfDNA detection, analysis, and clinical applications, and discuss future research directions.
登录
查看更多内容
DOI：
10.1158/1078-0432.ccr-15-0584
发表时间：
2015-10-15
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
Frenel JS;Carreira S;Goodall J;Roda D;Perez-Lopez R;Tunariu N;Riisnaes R;Miranda S;Figueiredo I;Nava-Rodrigues D;Smith A;Leux C;Garcia-Murillas I;Ferraldeschi R;Lorente D;Mateo J;Ong M;Yap TA;Banerji U;Gasi Tandefelt D;Turner N;Attard G;de Bono JS
通讯作者：
de Bono JS
影响因子：
22.7
作者：
Bratman, Scott V.;Yang, S. Y. Cindy;Pugh, Trevor J.
通讯作者：
Pugh, Trevor J.
影响因子：
24.5
作者：
Church TR;Wandell M;Lofton-Day C;Mongin SJ;Burger M;Payne SR;Castaños-Vélez E;Blumenstein BA;Rösch T;Osborn N;Snover D;Day RW;Ransohoff DF;PRESEPT Clinical Study Steering Committee, Investigators and Study Team
通讯作者：
PRESEPT Clinical Study Steering Committee, Investigators and Study Team
影响因子：
44.1
作者：
Cui Y;Chen H;Xi R;Cui H;Zhao Y;Xu E;Yan T;Lu X;Huang F;Kong P;Li Y;Zhu X;Wang J;Zhu W;Wang J;Ma Y;Zhou Y;Guo S;Zhang L;Liu Y;Wang B;Xi Y;Sun R;Yu X;Zhai Y;Wang F;Yang J;Yang B;Cheng C;Liu J;Song B;Li H;Wang Y;Zhang Y;Cheng X;Zhan Q;Li Y;Liu Z
通讯作者：
Liu Z
使用下一代测序进行循环肿瘤 DNA 分析的技术进展。
影响因子：
3.3
作者：
Bai, Yunfei;Wang, Zexin;Ge, Qinyu
通讯作者：
Ge, Qinyu